Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
February is American Heart Month - Expert with Bayer Discusses Key Risk Factors for Heart Disease and Shares Practical Tips for Improving Heart Health
Bayer: A Contrarian Thesis
08:36am, Sunday, 23'rd Feb 2025
Bayer's diversified portfolio and robust late-stage pharmaceutical pipeline are expected to stabilize revenues despite LoE concerns, particularly with Xarelto facing generic competition. The Crop Scie
Bayer® Aspirin Continues Longstanding Commitment to Heart Health Education, Encouraging Americans to “See Their Risks”
09:57am, Tuesday, 18'th Feb 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--In the United States alone, 104 million people are at risk of cardiovascular disease, and in a study of those that experienced a heart attack at age 50 or younger, hal
Bayer Unveils Latest Data from Prostate Cancer Portfolio at 2025 ASCO GU Cancers Symposium
08:00am, Tuesday, 11'th Feb 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Unveils Latest Data from Prostate Cancer Portfolio at 2025 ASCO GU Cancers Symposium.
Expanding Access to Healthcare Services, Medical Tourism & Healthcare Investments Among the Key Trends Expanding Access to Healthcare Services, Medical Tourism & Healthcare Investments Among the Key T
IQ-AI's Imaging Biometrics expands distribution deal with Bayer's Blackford
03:04am, Monday, 03'rd Feb 2025
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) subsidiary Imaging Biometrics has expanded its distribution agreement with artificial intelligence imaging platform provider Blackford Analysis, which is an arm of
Bayer AG Enterprise Digital Transformation Strategy Report 2024: Accelerators, Incubators, and Innovation Programs
04:22am, Monday, 20'th Jan 2025
Dublin, Jan. 20, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering.
Leaps by Bayer Announces One of the Largest Global Surveys of Society's Attitudes Toward Breakthrough Technologies
03:00am, Monday, 20'th Jan 2025
BERLIN--(BUSINESS WIRE)--As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the
WHIPPANY, N.J.--(BUSINESS WIRE)--A new survey commissioned by One A Day®, the multivitamin and supplement brand by Bayer rooted in more than 80 years of nutritional science, suggests that societal pr
YourUpdateTV Speaks with Kelly Bristow from Bayer About Simple Tips for a Healthier 2025
10:16am, Friday, 17'th Jan 2025
Registered Dietitian & Nutritionist from Bayer, Kelly Bristow, Shares Expert Tips to Help You Kickstart Your Health and Wellness Journey Registered Dietitian & Nutritionist from Bayer, Kelly Bristow,
Bayer must pay $100 million in latest trial over PCBs in Washington school, jury finds
05:12pm, Tuesday, 14'th Jan 2025
A Washington state jury on Tuesday said Bayer must pay $100 million to four people who say they were sickened by exposure to toxic chemicals known as PCBs made by the company's predecessor Monsanto th
Bayer's Pharma Growth Strategy Progressing Well as Pipeline Advances
01:30pm, Tuesday, 14'th Jan 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple
Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Copper Ammonium Carbonate Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The copper ammonium carbonate
Bayer pharma chief sees no big acquisitions in near future
02:23am, Tuesday, 14'th Jan 2025
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview published on Tue
Bayer's investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
11:22am, Friday, 10'th Jan 2025
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an in
